Heat Biologics (HTBX) Trading Down 4.3%

Share on StockTwits

Shares of Heat Biologics Inc (NASDAQ:HTBX) fell 4.3% during trading on Wednesday . The company traded as low as $1.32 and last traded at $1.32. 12,297 shares were traded during mid-day trading, a decline of 97% from the average session volume of 488,476 shares. The stock had previously closed at $1.38.

A number of research firms recently commented on HTBX. HC Wainwright set a $6.00 target price on shares of Heat Biologics and gave the stock a “buy” rating in a report on Friday, November 16th. ValuEngine upgraded shares of Heat Biologics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

Heat Biologics (NASDAQ:HTBX) last released its earnings results on Thursday, November 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.05. The business had revenue of $1.84 million for the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative net margin of 331.02% and a negative return on equity of 94.53%. As a group, research analysts forecast that Heat Biologics Inc will post -1.1 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp purchased a new position in shares of Heat Biologics in the second quarter worth approximately $111,000. Vanguard Group Inc. increased its position in shares of Heat Biologics by 20.6% in the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock worth $1,597,000 after acquiring an additional 136,256 shares in the last quarter. Vanguard Group Inc increased its position in shares of Heat Biologics by 20.6% in the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock worth $1,597,000 after acquiring an additional 136,256 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Heat Biologics in the fourth quarter worth approximately $55,000. 4.46% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Heat Biologics (HTBX) Trading Down 4.3%” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4081057/heat-biologics-htbx-trading-down-4-3.html.

Heat Biologics Company Profile (NASDAQ:HTBX)

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

See Also: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Set Workday Inc  Price Target at $158.74
Analysts Set Workday Inc Price Target at $158.74
Lam Research Co.  Given Consensus Recommendation of “Buy” by Analysts
Lam Research Co. Given Consensus Recommendation of “Buy” by Analysts
Teck Resources  Shares Up 5.1%
Teck Resources Shares Up 5.1%
Five9  Trading Down 5.2%
Five9 Trading Down 5.2%
Albemarle  Releases FY 2019 Earnings Guidance
Albemarle Releases FY 2019 Earnings Guidance
Espers  Price Reaches $0.0001 on Major Exchanges
Espers Price Reaches $0.0001 on Major Exchanges


© 2006-2019 Ticker Report